Epigenetics Drugs and Diagnostic Technologies Market is valued at USD 7.71 Billion in 2018 and expected to reach USD 27.13 Billion by 2025 with the CAGR of 19.68% over the forecast period.
Growing prevalence of oncological and non-oncological conditions like respiratory diseases, alzheimer disease and growing R & D investments in the healthcare industries promotes the growth of global epigenetics drugs and diagnostic technologies market.
Epigenetics is a study of heritable variations in gene expression; it is a trait change without genotype alteration. Epigenetic change is a normal and natural phenomenon but can also be affected by a variety of factors like age, environment or lifestyle and disease state. New and ongoing work continues to uncover the role of epigenetics in a variety of human disorders and fatal diseases. Many diseases are affected by epigenetic processes, including cancer, heart disease, diabetes and mental illnesses. Epigenetic therapy provides a potential way to directly influence those pathways. Epigenetic drugs and diagnostics are used in early stage cancer screening, as well as other pathological modifications in skin cells, liver cells, brain cells and others. Epigenetic test kits are used to diagnose diseases due to early-stage epigenetic changes and during therapy to verify the therapeutic efficacy. They work by involving modification-specific monoclonal antibodies, based on immunoprecipitation. Epigenetic drugs belong to a group of medications which are used to treat different cancers and other diseases like respiratory diseases, alzheimer disease. Those drugs fall into two groups which are methylation inhibitors of DNA and inhibitors of histone deacetylase. There are seven cancer care drugs have been licensed by the FDA. Also epigenetic drugs used in sensitization of chemotherapy, radiotherapy, and modulation of immune system.
Get Sample Copy of This Premium Report: @ https://brandessenceresearch.com/requestSample/PostId/1242
The global epigenetics drugs and diagnostic technologies market is segmented on the basis of product, type of therapy, technology, application and region and country level. On the basis of product, the global epigenetics drugs and diagnostic technologies market is segmented into reagents, kits, instruments, enzymes and services. Based on type of therapy, the epigenetics drugs and diagnostic technologies market is classified into histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors. On the basis of technology, the global epigenetics drugs and diagnostic technologies market is segmented into DNA methylation, histone methylation, histone acetylation, large non-coding RNA, microRNA modification and chromatin structures. On the basis of application, the global epigenetics drugs and diagnostic technologies market is segmented into oncology and non-oncology.
The regions covered in global Epigenetics Drugs and Diagnostic Technologies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global Epigenetics Drugs and Diagnostic Technologies Market sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Epigenetics Drugs and Diagnostic Technologies Companies
Global Epigenetics Drugs and Diagnostic Technologies Market reports cover prominent players,
Thermo Fisher Scientific
Abcam, Eisai Co. Ltd
Syndax Pharmaceuticals, Inc.
Chroma Therapeutics Ltd
Novartis International AG
Oncolys Biopharma Inc
Global Epigenetics Drugs and Diagnostic Technologies Market Dynamics –
The key factor responsible for the growth of the epigenetics drugs and diagnostic technologies market is growing prevalence of oncological and non-oncological conditions like respiratory diseases, alzheimer’s disease. Cancer is a leading cause of death for children and adolescents worldwide and about 300,000 children aged 0 to 19 are diagnosed with cancer every year. More than 80 % of children with cancer are cured in high-income countries but only around 20 % are cured in many low- and middle-income countries. Cancer is the world's second leading cause of death, and is responsible for estimated deaths of 9.6 million in 2018. Overall, cancer causes about 1 in 6 deaths. In low- and middle-income countries, approximately 70 % of cancer deaths occur. Tobacco use is the most important risk factor for cancer, and is responsible for about 22% of deaths from cancer. According to WHO more than 3 million people die each year from COPD, an estimated 6% of all deaths worldwide.
Another factor which drives the epigenetics drugs and diagnostic technologies market is growing R & D investments in the healthcare industries. Pharmaceutical industries spent nearly USD 179.55 Billion on research and development. While spending on marketing in healthcare industry in 2016 was around USD 31 Billon. Nonetheless, Quality-related problems and lack of knowledge are likely to restrain the epigenetics drugs and diagnostic technologies market to certain extent. Introduction of technologically advanced products will create new opportunities for epigenetics drugs and diagnostic technologies market over the forecast period.
Epigenetics Drugs and Diagnostic Technologies Market Regional Analysis –
North America dominates the global market owing to factors such as high prevalence of cancer, increased support for R&D. In 2019, the United States was spent around 581 billion U.S. dollars into research and development according to Statisca. More than 25 million people have asthma in the United States, About 14.8 million adults have been diagnosed with COPD and about 12 million people have not yet been diagnosed with COPD in 2019.
The Asia Pacific is the expected to emerge as the fastest-growing epigenetics drugs and diagnostic technologies market due to significant number of cancer, diabetes and other chronic diseases with related unmet medical needs. In 2016, there were around 3.8 million new cases of and 2.3 million deaths caused by malignant tumors. That is, 7 people were diagnosed with cancer on average while 4 people died from cancer every minute in China.
Key Benefits for Epigenetics Drugs and Diagnostic Technologies Market reports –
Global Epigenetics Drugs and Diagnostic Technologies Market report covers in depth historical and forecast analysis.
Global Epigenetics Drugs and Diagnostic Technologies Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global Epigenetics Drugs and Diagnostic Technologies Market report helps to identify opportunities in market place.
Global Epigenetics Drugs and Diagnostic Technologies Market report covers extensive analysis of emerging trends and competitive landscape.
Epigenetics Drugs and Diagnostic Technologies Market Segmentation –
By Product: Reagents, Kits, Instruments, Enzymes, Services
By Type of Therapy: Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors
By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Non-Coding RNA, MicroRNA Modification, Chromatin Structures
By Application: Oncology, Non-Oncology
Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at firstname.lastname@example.org
Interested in this report?